NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

HMR59:新興醫藥品的洞察與到2030年前的市場預測

HMR59- Emerging Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 973302
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 10個工作天內
價格
HMR59:新興醫藥品的洞察與到2030年前的市場預測 HMR59- Emerging Drug Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

本報告提供7個主要市場(美國,歐洲5個國家(德國,法國,義大利,西班牙,英國),日本)的HMR59市場的相關調查,刊載產品概要,2020年到2030年的預測銷售額資料,臨床實驗干預,臨床實驗條件,臨床實驗情形,涵括開始日和完成日的臨床試驗資訊,競爭情形,各國市場評估等資訊。

目錄

第1章 藥物概要

  • 產品詳細內容
  • 作用機制
  • 投藥和管理
  • 研究開發活動
    • 臨床開發
    • 安全性和有效性
  • 其他開發活動

第2章 市場評估

  • 主要7個國家 (7MM) 市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 義大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章 SWOT分析

第4章 分析師的見解

第5章 市場競爭

第6章 其他的新治療方法

第7章 附錄

第8章 購買報告的選擇

目錄
Product Code: DIDM0103

"HMR59- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Geographic Atrophy in 7 Major Markets. A detailed picture of the HMR59 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

CD59 is a protective protein that is normally found on the plasma membrane of cells. CD59 protects cells from a natural inflammatory cascade in the body called complement that acts as a part of the body's nonspecific immune response. An overactivity of complement is felt to be the cause of macular degeneration. Studies have also shown that patients with AMD have less CD59 present in the retina to protect their cells from damage caused by complement. Hemera's gene therapy that is under FDA approved clinical testing to treat both the dry and wet forms of AMD is called HMR59. HMR59 injected in the eye increases the ability of retina cells to make a soluble form of CD59 called sCD59. The soluble CD59 circulates within the retina to block complement from further damaging the retina.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around HMR59.
  • The report contains forecasted sales for HMR59 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Geographic Atrophy.
  • The report also features the SWOT analysis with analyst insights and key findings of HMR59.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

HMR59 Analytical Perspective by DelveInsight

  • In-depth HMR59 Market Assessment

This report provides a detailed market assessment of HMR59 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • HMR59 Clinical Assessment

The report provides the clinical trials information of HMR59 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Geographic Atrophy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence HMR59 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Geographic Atrophy are giving market competition to HMR59 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of HMR59.
  • Our in-depth analysis of the forecasted sales data of HMR59 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the HMR59.

Key Questions:

  • Which company is developing HMR59 along with the phase of the clinical study?
  • What is the technology utilized in the development of HMR59?
  • What is the product type, route of administration and mechanism of action of HMR59?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HMR59 development?
  • What are the key designations that have been granted to HMR59?
  • What is the forecasted market scenario of HMR59?
  • What is the history of HMR59 and what is its future?
  • What is the forecasted sales of HMR59 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to HMR59?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 HMR59, Description
  • Table 2 HMR59, Clinical Trial Description
  • Table 3 HMR59, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of HMR59
  • Figure 2 Patent Details, HMR59
  • Figure 3 HMR59, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 HMR59, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 HMR59, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 HMR59, Japan Market Size from 2020 to 2030 (in Millions USD)